Hair cortisol and endocannabinoid measurement in patients with adrenal incidentalomas: a case-control study
- PMID: 37792214
- DOI: 10.1007/s42000-023-00495-x
Hair cortisol and endocannabinoid measurement in patients with adrenal incidentalomas: a case-control study
Abstract
Purpose: The role of endocannabinoids (ECs) in the regulation of the hypothalamic-pituitary-adrenocortical axis has already been studied; however, data are scarce in humans. The aim of our study was to analyze EC [anandamide (AEA) and 2-arachidonoylglycerol (2-AG)] and cortisol (F) levels in hair samples of patients with adrenal incidentalomas (AIs) in comparison with those found in controls and assess their association with the hormone profile.
Methods: Forty-four patients with AIs [32 with non-functioning AIs (NFAIs) and 12 with possible autonomous secretion (PACS)] and 44 controls were recruited. Basal and post-1 mg overnight dexamethasone suppression test (ODST) F, adrenocorticotropic hormone, dehydroepiandrosterone sulfate, and 24-h urinary free cortisol were analyzed. After hair collection, EC and F levels were measured by liquid chromatography tandem-mass spectrometry.
Results: There was no difference between the groups regarding age, sex, and metabolic status. Significantly decreased hair AEA and 2-AG levels were found in patients with AIs compared to controls (p < 0.001 and p = 0.002, respectively) as well as between NFAI or PACS and controls (p < 0.001 or p = 0.002 and p = 0.038 or p = 0.02, respectively). Among the AI patients, EC levels tended to be lower in the PACS group. AEA hair levels were negatively correlated with F levels post-1 mg ODST (rs = -0.257, p = 0.033). We found no significant difference comparing hair F between the groups.
Conclusion: Our findings suggest that hair EC measurement could be a potential biomarker in the evaluation of patients with AIs, whereas hair F analysis is not a useful diagnostic test for mild hypercortisolemia.
Keywords: Adrenal mass; Cortisol; Endocannabinoids; Hair biomarkers.
© 2023. The Author(s), under exclusive licence to Hellenic Endocrine Society.
Similar articles
-
Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?Endocrine. 2023 Oct;82(1):161-170. doi: 10.1007/s12020-023-03429-0. Epub 2023 Jun 23. Endocrine. 2023. PMID: 37351760
-
Limited Role of Hair Cortisol and Cortisone Measurement for Detecting Cortisol Autonomy in Patients With Adrenal Incidentalomas.Front Endocrinol (Lausanne). 2022 Feb 8;13:833514. doi: 10.3389/fendo.2022.833514. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35222288 Free PMC article.
-
Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion.J Clin Endocrinol Metab. 2014 Aug;99(8):2754-62. doi: 10.1210/jc.2013-4064. Epub 2014 Apr 8. J Clin Endocrinol Metab. 2014. PMID: 24712565
-
Cardiometabolic profile and urinary metabolomic alterations in non-functioning adrenal incidentalomas: A review.Clin Endocrinol (Oxf). 2022 Dec;97(6):693-701. doi: 10.1111/cen.14745. Epub 2022 Apr 27. Clin Endocrinol (Oxf). 2022. PMID: 35451056 Review.
-
Diabetes Mellitus in Non-Functioning Adrenal Incidentalomas: Analysis of the Mild Autonomous Cortisol Secretion (MACS) Impact on Glucose Profile.Biomedicines. 2024 Jul 18;12(7):1606. doi: 10.3390/biomedicines12071606. Biomedicines. 2024. PMID: 39062179 Free PMC article. Review.
Cited by
-
Genetics of primary hyperparathyroidism, our first Batrinos' scholar review, metabolic syndrome, and quite a bit of reproductive endocrinology: a great issue.Hormones (Athens). 2024 Mar;23(1):1-2. doi: 10.1007/s42000-023-00523-w. Hormones (Athens). 2024. PMID: 38195949 No abstract available.
-
Advances in targeted liquid chromatography-tandem mass spectrometry methods for endocannabinoid and N-acylethanolamine quantification in biological matrices: A systematic review.Mass Spectrom Rev. 2025 May-Jun;44(3):513-538. doi: 10.1002/mas.21897. Epub 2024 Jul 3. Mass Spectrom Rev. 2025. PMID: 38958096 Free PMC article.
References
-
- Fassnacht M, Arlt W, Bancos I et al (2016) Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 175(2):G1–G34. https://doi.org/10.1530/EJE-16-0467 - DOI - PubMed
-
- Aresta C, Favero V, Morelli V, et al. (2021) "Cardiovascular complications of mild autonomous cortisol secretion," 2021 Best Pract Res Clin Endocrinol Metab 35(2):101494. https://doi.org/10.1016/j.beem.2021.101494
-
- Chiodini I, Vainicher CE, Morelli V et al (2016) MECHANISMS IN ENDOCRINOLOGY: Endogenous subclinical hypercortisolism and bone: a clinical review. Eur J Endocrinol 175(6):R265-r282. https://doi.org/10.1530/EJE-16-0289 - DOI - PubMed
-
- Deutschbein T, Reimondo G, Di Dalmazi G et al (2022) Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol 10(7):499–508. https://doi.org/10.1016/S2213-8587(22)00100-0 - DOI - PubMed - PMC
-
- Hodes A, Meyer J, Lodish MB et al (2018) Mini-review of hair cortisol concentration for evaluation of Cushing syndrome. Expert Rev Endocrinol Metab 13(5):225–231. https://doi.org/10.1080/17446651.2018.1517043 - DOI - PubMed - PMC
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical